Lixte Biotechnology (NASDAQ:LIXT) Posts Earnings Results

Lixte Biotechnology (NASDAQ:LIXT) announced its earnings results on Monday. The company reported ($0.27) earnings per share (EPS) for the quarter, Zacks reports.

Lixte Biotechnology Price Performance

Shares of NASDAQ LIXT opened at $1.29 on Monday. The stock has a market capitalization of $2.90 million, a P/E ratio of -0.75 and a beta of 0.19. Lixte Biotechnology has a 1-year low of $1.02 and a 1-year high of $4.40. The business’s 50 day moving average is $1.81 and its two-hundred day moving average is $1.89.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.